We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Canada Finalizes Recommendations on 3rd-Party Data in Drug Submissions
Canada Finalizes Recommendations on 3rd-Party Data in Drug Submissions
Sponsors seeking Canadian approval of new drugs or indications based on published literature or postmarketing data need to be able to prove that their drug is comparable to its reference product, regulators say.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor